IP Library Granted Patent US 7,153,650
Granted Patent B2
US 7,153,650 · App. 10/389,431 · Granted Dec 26, 2006

Marker system for preparing and characterizing high-quality human embryonic stem cells

Assignee: Geron Corporation
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,153,650
App. No.
10/389,431
Granted
Dec 26, 2006
Kind
B2
Abstract

This disclosure provides a system for qualifying embryonic stem cells intended for human therapy. A large-scale sequencing project has identified important markers that are characteristic of undifferentiated pluripotent cells. Combinations of these markers can be used to validate the self-renewing capacity of ES cells, and their ability to differentiate into tissue types suitable for regenerative medicine. The marker system of this invention has been used to screen feeder cells, media additives, and culture conditions that promote proliferation of stem cells without differentiation. A culture system optimized by following these markers is suitable for rapid expansion of undifferentiated cells from existing lines, or the derivation of new lines that are equally apposite for clinical use.

Claims (6)

1. A method for assessing the differentiation of a population of human embryonic stem cells in vitro, comprising measuring the gastrin-releasing peptide (GRP) receptor expression level in the population of human embryonic stem cells; wherein a decrease in the GRP receptor expression level relative to the GRP receptor expression level measured in the population at an earlier time point indicates that the population is differentiating.

2. The method of claim 1 , wherein the GRP receptor expression level is measured at the mRNA level.

3. The method of claim 2 , wherein the GRP receptor expression level is measured at the mRNA level by PCR amplification.

4. The method of claim 1 , wherein the GRP receptor expression level is measured at the protein level.

5. The method of claim 4 , wherein the GRP receptor expression level is measured at the protein level by antibody assay.

6. The method of claim 1 , wherein the GRP receptor expression level is measured using flow cytometry.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 12, 2013
From: GERON CORPORATION
To: ASTERIAS BIOTHERAPEUTICS, INC.
Reel/Frame 031620/0567 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 11, 2003
From: STANTON, LAWRENCE W.; BRANDENBERGER, RALPH; GOLD, JOSEPH D.; IRVING JOHN M.; MANDALAM, RAMKUMAR; MOK, MICHAEL
To: GERON CORPORATION
Reel/Frame 013794/0403 →
Continuity (1)
Related Publication 20040180347A1 · Sep 16, 2004